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Abstract
Background: Many candidate genes have been reported to be risk factors for acute coronary
syndrome (ACS), but their impact on clinical prognosis following ACS is unknown.
Methods: We examined the association of putative genetic risk factors with 3-year post-ACS
mortality in 811 ACS survivors at university-affiliated hospitals in Kansas City, Missouri. Through a
systematic literature search, we first identified genetic variants reported as susceptibility factors for
atherosclerosis or ACS. Restricting our analysis to whites, so as to avoid confounding from racial
admixture, we genotyped ACS cases for 89 genetic variants in 72 genes, and performed individual
Kaplan-Meier survival analyses. We then performed Cox regression to create multivariate risk
prediction models that further minimized potential confounding.
Results: Of 89 variants tested, 16 were potentially associated with mortality (P < 0.1 for all), of
which 6 were significantly associated (P < 0.05) with mortality following ACS. While these findings
are not more than what would be expected by chance (P = 0.28), even after Bonferroni correction
and adjustment for traditional cardiac risk factors, the IRS1 972Arg variant association (P = 0.001)
retained borderline statistical significance (P < 0.1).
Conclusion: With the possible exception of IRS1, we conclude that multiple candidate genes were
not associated with post-ACS mortality in our patient cohort. Because of power limitations, the 16
gene variants with P values < 0.1 may warrant further study. Our data do not support the
hypothesis that the remaining 73 genes have substantial, clinically significant association with
mortality after an ACS.
Background
Despite convincing evidence of heritable susceptibility to
acute coronary syndromes (ACS), including unstable
angina (UA), non-ST elevation myocardial infarction
(NSTEMI), and ST-elevation myocardial infarction
(STEMI),[1] most common genetic variants have yet to be
validated conclusively as ACS risk factors. [2-4] We
recently reported an attempt to validate putative cardiac
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risk factors,[5] all of which had been previously published
in significant association with ACS or atherosclerosis,
finding that only one pre-specified genetic risk genotype,
homozygosity for the -455 A/G promoter variant in B-
fibrinogen, could be replicated in our sample of 811 ACS
cases and 650 controls. We concluded that our results did
not support previous hypotheses generated by the candi-
date gene approach to ACS and that better study designs
and unbiased screening approaches, such as whole
genome association studies that have implicated 5 vari-
ants in the 9p21 region as ACS susceptibility factors,[6,7]
would be needed.
However, it is not yet known if candidate gene variants,
including those in the 9p21 region, will affect prognosis
following ACS. In theory, genes associated with the devel-
opment of clinically significant atherosclerosis may also
have a strong impact on subsequent prognosis after an
ACS event has occurred. In particular, those who have
already suffered ACS are at very high risk for suffering a
subsequent fatal or nonfatal cardiac event, due not only to
post-ACS physiological vulnerability, but also to the
genetic and environmental risk factor profiles that led to
the initial cardiac event. Against this backdrop of height-
ened risk, individual genetic effects may be markedly
potentiated. With so many individuals currently surviving
ACS events worldwide, there is an urgent need to identify
improved methods for risk-stratifying patients' post-ACS
prognosis so that more aggressive efforts at secondary pre-
vention or intracardiac defibrillator insertion can be con-
sidered. Moreover, the identification of clinically
important genetic risks for an adverse outcome after an
ACS can also identify new targets for potential interven-
tion. Despite the importance of such investigations, few
studies have examined the association of potential ather-
ogenic risk factors on prognosis after an ACS. To stimulate
this line of research, we have performed a longitudinal
follow-up study to investigate the impact of 89 candidate
gene variants on mortality following ACS.
Methods
Candidate genes
Our search strategy for putative risk variants, along with a
list of references for each variant, has been described pre-
viously,[5] and further details about each gene variant,
including flanking DNA sequences, are available upon
request from the authors. Reports were included if they
contained a claim of a significant positive association,
with an investigator-reported P value < 0.05. Medline
search terms included: "gene, genetic, polymorphism,
myocardial infarction, atherosclerosis, coronary heart dis-
ease, and coronary artery disease." In addition to the gene
variants contained in our initial report, we genotyped the
5 variants in the 9p21 region that have recently been
implicated in the occurrence of myocardial infarction.
Overall, we identified, and successfully genotyped, 89 var-
iants in 72 genes (or gene regions, in the case of 9p21,
given that a causative mechanism has not yet been identi-
fied).
Study population and genotyping
Eight hundred eleven self-reported white patients of Euro-
pean ancestry with ACS were identified from a consecutive
series of patients presenting to two Kansas City, MO hos-
pitals (Mid-America Heart Institute and Truman Medical
Center), from March 2001 through June 2003. Standard
definitions were used to diagnose ACS patients with either
myocardial infarction or unstable angina.[8,9] Individu-
als were monitored for incident deaths from any cause, as
determined by periodic queries of the Social Security
Administration Death Master File.[10] A minimum of 3
years of follow-up was available.
Genotyping was performed using the Sequenom MALDI-
TOF (Matrix Assisted Laser Desorption-Ionization Time-
of-Flight)[11,12] system on whole genome amplified
DNA.[13,14] More extensive details of the cases and gen-
otyping procedures have been recently described.[5]
Statistical Analysis
Genotype distributions were examined for significant
deviation (P < 0.05) from Hardy-Weinberg equilibrium.
PHASE Version 2.1 was used to estimate haplotype fre-
quencies for ALOX5AP.[15,16]
Initially, Kaplan-Meier survival analysis was performed
for each variant (SAS 9.1, Research Triangle Park, NC).
Cox regression models were then used to adjust positive
associations for cardiac risk factors (age, sex, hyperten-
sion, congestive heart failure, diabetes), type of ACS
(STEMI, NSTEMI, UA), and ACS treatments (aspirin and
beta-blocker treatments provided in the first 24 hours, the
use of angiography and revascularization, as well as qual-
ity of care indicators rendered at discharge (aspirin, beta-
blocker, ACE inhibitor, and smoking cessation coun-
seling)). We tested the proportional-hazards assumption
for each covariate, by correlating the corresponding set of
scaled Schoenfeld residuals with a suitable transformation
of time based on the Kaplan-Meier estimate of the survival
function. We applied the conservative Bonferroni correc-
tion in considering the overall statistical significance of
results,[17] but we also simply compared the total
number of all positive associations at the P < 0.05 level to
the expected number by chance, in 50,000 simulations
(Resampling Stats, Inc., College Park, MD). An unex-
pected surplus of positive associations would imply that
some of the tested polymorphisms may be truly associ-
ated with ACS.
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Our sample had 93% power to detect an association, by
the log rank test (P < 0.05), for a hazard ratio of 2.5 or
higher, given a frequent genotype (0.5), and 80% power
to detect a hazard ratio of 3.3 or higher, given an infre-
quent genotype (0.1).[18] For weak effects (1.1–1.5 haz-
ard ratio), power was limited, ranging from 5% (0.1
genotype frequency, 1.1 hazard) to 29% (0.5 genotype
frequency, 1.5 hazard). Given that such genetic variants
with modest effects may not reach the conventional statis-
tical significance level of P < 0.05, we sought to explore
the possibility that null results might be related to lack of
power (type II error), by examining the characteristics of
the overall P value distribution. A Q-Q plot was per-
formed, and supplemented with a simulation-based anal-
ysis. Random P values follow the Beta distribution.
Hence, we subtracted random numbers between 0 and 1
(Beta distribution) from the observed P values, computed
mean (observed-random) differences across all genetic
variants, repeated this procedure 50,000 times, and plot-
ted frequency histograms of the resulting 50,000 mean
differences (Resampling Stats, Inc). In the presence of
multiple bona fide genetic risk factors, but suboptimal
power, the average mean P value difference (observed-
random) would be less than zero. We initially included all
P values from the individual Kaplan-Meier log-rank tests
for all 89 genetic variants, and then sequentially removed
those with the lowest P values until the remaining subset
converged to a difference equal to zero, as would be
expected for random variables showing no evidence of
association with ACS.
Results
The clinical characteristics of the 811 cases are described
in Table 1. The population of ACS cases included 308
(38%) STEMI, 284 (35%) NSTEMI, and 219 (27%) UA
patients. A family history of coronary artery disease or
myocardial infarction among first degree relatives was
found in over half of cases. In addition, cardiac risk factor
profiles were typical of a population with ACS, with over
one half of patients having hypercholesterolemia and
hypertension, a third with a history of smoking, and over
one fifth with diagnosed diabetes. Previous revasculariza-
tion had been performed in over a third of the ACS cases.
There were 90 deaths in the cohort, which was followed
for a median time of 42.3 months. Risk factor data used in
the multivariable models were missing for 2 individuals.
Those individuals who died, as compared to survivors, did
not differ significantly in sex (P = 0.33) or ACS type (P =
0.22). However, there were marked differences in overall
cardiac risk factor profiles, as expected, with deceased
patients having relatively advanced age, as well as more
extensive cardiovascular comorbidity such as congestive
heart failure (Table 2).
A total of 89 variants in 72 genes were genotyped. The
overall genotype call rate for these variants was 98.5%
(range 95.0–99.8%). Tests of Hardy Weinberg equilib-
rium revealed that 6 variants violated HWE at the P < 0.05
level, which is not more than expected by chance (P =
0.29), given 89 chi-square tests (Table 2).
The genotype distributions, numbers of deaths by geno-
typic category, and unadjusted P values for all 89 genetic
variables are shown in Table 3. Overall, there were 6 pos-
itive associations (P < 0.05). Despite their established
association with ACS, none of the 9p21 variants was asso-
ciated with prognosis. Likewise, the -455 A/G promoter
variant in B-fibrinogen, which had been weakly associated
with ACS occurrence in our study population, was not
associated with post-ACS mortality (P = 0.1). However,
the ACE1 I/I genotype was associated with a lower survival
time (P = 0.04). In addition, the APOA1 -75G/A polymor-
phism was associated with mortality (early death of a sin-
Table 1: Characteristics of 811 white subjects with acute coronary syndrome at baseline
Characteristic Male ACS Cases (N = 550) Female ACS Cases (N = 261)
Mean age in years (SD) 60.7 (12.5) 63.1 (13.2)
Mean body mass index (SD) 29.1 (5.5) 29.9 (6.9)
Family history of CAD/MI (%) 279 (50.7) 135 (51.7)
Prior myocardial infarction(%) 142 (25.8) 74 (28.4)
Prior revascularization (%) 205 (37.3) 83 (31.8)
Congestive heart failure (%) 23 (4.2) 18 (6.9)
Hypertension (%) 305 (55.5) 182 (69.7)
Diabetes Mellitus (%) 116 (21.1) 77 (29.5)
Hypercholesterolemia (%) 314 (57.1) 162 (62.1)
Postmenopausal (%) -- 189 (68.6)
College graduate (%) 166 (30.2) 40 (15.3)
Smoking <30 days ago (%) 183 (33.3) 85 (32.6)
Alcohol frequency > 1/month (%) 221 (40.2) 38 (14.6)
Continuous variables are shown as mean (SD); categorical variables are number (%)
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gle individual with the rare A/A genotype). Survival time
was relatively decreased among the 16 individuals with
the rare A/A (glutamine homozygous) genotype of the F7
Arg353Gln polymorphism (P = 0.01), with 5 deaths in
this group. There was also excess mortality among hetero-
zygotes for the HFE hemochromatosis-related allele (P =
0.04). In addition, individuals with the A/A genotype
(lysine homozygotes) of the ICAM1 Lys469Glu missense
mutation had an increased mortality risk (P = 0.01).
Finally, the strongest statistical association with post-ACS
mortality was observed in IRS1 arginine homozygotes,
owing mainly to 2 early deaths among the 3 individuals
with the rare A/A genotype in the Gly972Arg polymor-
phism; the deceased individuals were two males, aged 71
and 72 years, respectively, both of whom had extensive
cardiac risk factor profiles. Heterozygotes had relatively
low risk of death compared with homozygotes.
Of the 6 positive associations described above, 2
remained significant following Cox regression adjustment
for traditional cardiac risk factors including age, sex,
hypertension, diabetes, congestive heart failure, and ACS
type, as well as treatment-related factors. Of these covari-
ates, age (P < 0.0001), diabetes (P < 0.0001), and lack of
revascularization (P < 0.01) had the most significant asso-
ciations with mortality when modeled independent of
genotype. The G allele of IRS1 was related to longer sur-
vival, with adjusted hazard ratios of 0.08 (0.02, 0.84) for
A/G, and 0.23 (0.05, 0.99) for G/G, respectively. In addi-
tion, the ICAM1 association remained significant, only for
A/G heterozygotes (0.53; 95% CI: 0.33, 0.84), with the
reference genotype being A/A.
In order to further explore the data for potential weak
associations not quite meeting the P < 0.05 significance
threshold due to suboptimal power, we performed a sim-
ulation analysis as described above, to supplement visual
inspection of the Q-Q plot (Figure 1), which was not pre-
cisely linear. The mean difference that we observed was -
0.065 for all 89 genetic variables (Figure 2), indicating
that some P values were lower than expected by chance
alone. In addition to the 6 associations described above,
10 additional genetic variants had P values of 0.1 or lower.
Upon removal of these 16 positive associations (P < 0.1),
the mean difference converged to zero in the remaining
73 genetic variables (Figure 2), suggesting no probable
association with mortality.
Discussion
Of the 89 genetic variants tested, we found strong statisti-
cal evidence of an association for only one, the IRS1
Gly972Arg polymorphism, although it was based upon a
small number of deaths in individuals who would already
have been considered at high risk for mortality. Thus, we
can not unequivocally implicate any of the genetic vari-
ants included in this study as a prognostic factor following
ACS, including those in the 9p21 region. The possible
explanations for our essentially null findings include
inadequate power for survival analysis, given that mortal-
ity following ACS occurred in only 11.1% of our case sam-
ple, or that the genetic variants included in our study have
no impact on post-MI prognosis.
With respect to statistical power, we have presented evi-
dence that at least 73 of the gene variants seemed identical
to random variables, and therefore, our data provide no
support for the hypothesis that testing these particular var-
iants in larger samples would likely yield positive results.
It is unlikely that mortality in direct relation to any of
these gene variants is a common occurrence following
ACS. Furthermore, as shown in Table 1, conventional car-
diac risk factors such as advanced age and diabetes appear
to be dominant factors in determining prognosis, and
therefore, it may be challenging to demonstrate an inde-
pendent genetic effect on mortality without sample sizes
far in excess of 800 patients, particularly if genetic or phar-
macogenetic interactions are explored.
However, given the limitations of our sample size, we
were unable to exclude modest effects in association with
the remaining 16 gene variants, 6 of which had nominally
statistically significant associations with post-ACS mortal-
ity. Of these, only 2 remained significant after adjustment
for traditional cardiac risk factors, with ACE1, APOA1, F7,
and HFE having no independent association. As might
have been expected, known confounding variables such as
age, sex, and comorbidity proved to be important predic-
tors of mortality in the Cox regression models. In addi-
Table 2: Clinical characteristics of surviving and deceased 
patients in the follow-up cohort
Characteristic Survivors Deceased 
(N = 721) (N = 90)
Mean age in years (SD)‡ 60.5 (12.5) 69.5 (11.6)
Mean body mass index (SD) 29.4 (6.0) 28.8 (6.6)
Family history of CAD/MI (%) 374 (52.0) 40 (44.4)
Prior myocardial infarction(%)‡ 176 (24.5) 40 (44.4)
Prior revascularization (%)‡ 241 (33.5) 47 (52.2)
Congestive heart failure (%)‡ 28 (3.9) 13 (14.4)
Hypertension (%)* 423 (58.8) 63 (70.0)
Diabetes Mellitus (%)‡ 150 (20.9) 43 (47.8)
Hypercholesterolemia (%) 419 (58.3) 57 (63.3)
Postmenopausal (%) -- --
College graduate (%) 185 (25.9) 19 (21.6)
Smoking <30 days ago (%)* 249 (34.7) 18 (20.0)
Alcohol frequency > 1/month (%)‡ 348 (55.8) 19 (24.4)
Continuous variables are shown as mean (SD); categorical variables 
are number (%) P < 0.05, *† P < 0.01; ‡ P < 0.001 for comparison 
between deceased and survivors
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Table 3: Kaplan-Meier analysis of mortality post-ACS for 89 genetic variants.
Gene/SNP Genotype Total N Deaths (%) P Gene Genotype Total N Deaths (%) P
ABCA1 CC 191 18 (9.4) 0.50 ICAM1 AA 270 43 (15.9) 0.01
-477C/T CT 396 43 (10.9) Lys469Glu AG 379 32 (8.4)
TT 188 25 (13.3) GG 145 14 (9.7)
ABCA1 AA 65 7 (10.8) 0.47 IL1B CC 359 35 (9.8) 0.42
Lys219Arg AG 311 39 (12.5) -511C/T CT 311 33 (10.6)
GG 416 41 (9.9) TT 82 12 (14.6)
ACE1 DD 233 28 (12) 0.04 IL6 CC 142 16 (11.3) 0.59
I/D DI 389 35 (9) -174G/C CG 386 39 (10.1)
II 154 25 (16.2) GG 277 35 (12.6)
ADD1 GG 456 59 (12.9) 0.23 IRS1 AA 3 2 (66.7) 0.001
Gly460Trp GT 269 25 (9.3) Gly972Arg AG 84 4 (4.8)
TT 26 2 (7.7) GG 704 81 (11.5)
ADRB2 CC 266 36 (13.5) 0.19 ITGA2 AA 123 17 (13.8) 0.46
Glu27Gln* CG 358 33 (9.2) Phe807Phe AG 394 45 (11.4)
GG 146 15 (10.3) GG 288 28 (9.7)
ADRB2 CC 789 89 (11.3) 0.41 ITGB3 CC 20 3 (15) 0.89
Ile164Thr CT 18 1 (5.6) Leu33Pro CT 188 21 (11.2)
TT TT 588 64 (10.9)
ADRB2 AA 128 21 (16.4) 0.09 LIPC CC 506 59 (11.7) 0.79
Gly16Arg AG 348 36 (10.3) -514T/C CT 256 26 (10.2)
GG 309 31 (10) TT 42 5 (11.9)
ADRB3 CC 6 1 (16.7) 0.53 LPL AG 29 3 (10.3) 0.93
Arg64Trp CT 111 16 (14.4) Asp9Asn GG 765 86 (11.2)
TT 687 72 (10.5) GG
AGT CC 143 19 (13.3) 0.19 LRP1 AA 367 37 (10.1) 0.08
Thr235Met CT 387 48 (12.4) Thr3261Thr AG 330 46 (13.9)
TT 272 23 (8.5) GG 85 5 (5.9)
AGTR1 AA 388 48 (12.4) 0.56 LTA AA 394 44 (11.2) 0.52
A1166C AC 339 34 (10) A252G AG 327 38 (11.6)
CC 79 8 (10.1) GG 81 6 (7.4)
ALOX5AP A 123 12 (9.8) 0.61 LTA AA 80 6 (7.5) 0.51
HAP A non-A 648 74 (11.4) Thr26Asn AC 331 39 (11.8)
CC 389 44 (11.3)
ALOX5AP B 49 3 (6.1) 0.23 MGP AA 308 36 (11.7) 0.81
HAP B non-B 722 83 (11.5) Thr83Ala AG 374 39 (10.4)
GG 123 15 (12.2)
APOA1 AA 23 2 (8.7) 0.91 MGP AA 110 13 (11.8) 0.61
C83T AG 219 25 (11.4) -7A/G AG 368 37 (10.1)
GG 532 59 (11.1) GG 328 40 (12.2)
APOA1 AA 1 1 (100) 0.01 MMP3 DD 194 20 (10.3) 0.22
-75G/A AG 10 1 (10) indel DI 386 37 (9.6)
GG 784 87 (11.1) II 206 29 (14.1)
APOE E4/E4 29 1 (3.5) 0.20 MTHFR CC 350 39 (11.1) 0.53
E2-3-4 Non-E4 771 87 (11.3) Ala222Val CT 341 40 (11.7)
TT 102 8 (7.8)
APOE GG 194 25 (12.9) 0.42 MTP GG 449 54 (12) 0.13
-219T/G GT 403 47 (11.7) -493G/T GT 297 33 (11.1)
TT 206 18 (8.7) TT 59 2 (3.4)
BDKRB2 CC 263 25 (9.5) 0.40 MTR AA 529 56 (10.6) 0.15
-58C/T CT 394 50 (12.7) Asp919Gly AG 239 32 (13.4)
TT 145 14 (9.7) GG 34 1 (2.9)
CCL11 CC 539 64 (11.9) 0.76 NPPA CC 22 2 (9.1) 0.65
Thr23Ala CT 239 24 (10) Ter29ArgArg CT 190 18 (9.5)
TT 12 1 (8.3) TT 583 70 (12)
CCR2 AA 7 1 (14.3) 0.96 OLR1 CC 649 75 (11.6) 0.27
Val64Ile AG 116 12 (10.3) Lys167Asn CG 146 12 (8.2)
GG 681 77 (11.3) GG 8 2 (25)
CCR5 II 631 72 (11.4) 0.51 P22-PHOX CC 347 26 (7.5) 0.05
Indel ID 162 18 (11.1) His72Tyr** CT 271 36 (13.3)
DD 12 0 (0) TT 121 15 (12.4)
CD14 CC 204 25 (12.3) 0.22 PAI1 DD 249 32 (12.9) 0.33
-159C/T CT 395 47 (11.9) indel DI 398 38 (9.6)
TT 204 16 (7.8) II 159 20 (12.6)
CETP AA 168 13 (7.7) 0.13 PECAM1 CC 187 21 (11.2) 0.86
intron1 G/A AG 387 51 (13.2) Leu125Val CG 395 42 (10.6)
GG 250 25 (10) GG 222 27 (12.2)
CETP AA 205 18 (8.8) 0.39 PECAM1 AA 200 25 (12.5) 0.82
-629C/A AC 400 50 (12.5) Ser563Asn AG 386 42 (10.9)
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CC 197 21 (10.7) GG 214 22 (10.3)
COMT AA 231 17 (7.4) 0.06 PON1 AA 396 36 (9.1) 0.09
Val158Met AG 358 43 (12) Gln192Arg AG 337 47 (14)
GG 187 27 (14.4) GG 66 6 (9.1)
CX3CR1 CC 410 43 (10.5) 0.54 PON2 CC 464 56 (12.1) 0.43
Ile249Val CT 336 40 (11.9) Cys311Ser CG 298 28 (9.4)
TT 56 4 (7.1) GG 40 3 (7.5)
CX3CR1 AA 18 1 (5.6) 0.73 PPARG CC 637 73 (11.5) 0.32
Thr280Met AG 223 26 (11.7) Ala12Pro CG 159 15 (9.4)
GG 565 63 (11.2) GG 8 2 (25)
CYP11B2 CC 163 18 (11) 0.84 PTGS2 CC 15 2 (13.3) 0.94
-344T/C CT 352 42 (11.9) -765G/C CG 202 22 (10.9)
TT 275 29 (10.6) GG 576 65 (11.3)
CYP2C9 AA 708 79 (11.2) 0.89 RECQL2 CC 66 11 (16.7) 0.18
Leu359Ile AC 56 6 (10.7) Arg1367Cys CT 326 39 (12)
CC TT 412 39 (9.5)
CYP2C9 CC 589 63 (10.7) 0.83 SELE CC 658 71 (10.8) 0.43
Cys144Arg** CT 147 15 (10.2) Leu554Phe CT 137 18 (13.1)
TT TT 7 0 (0)
ENPP1 AA 600 64 (10.7) 0.75 SELE AA 740 82 (11.1) 0.89
Gln121Lys AC 192 24 (12.5) Ser128Arg AC 63 7 (11.1)
CC 15 2 (13.3) CC 2 0 (0)
ESR1 CC 145 21 (14.5) 0.32 SELP AA 646 71 (11) 0.48
-401T/C CT 421 41 (9.7) Thr715Pro AC 150 19 (12.7)
TT 239 27 (11.3) CC 9 0 (0)
F12 CC 459 51 (11.1) 0.73 TFPI AA
46C/T CT 283 32 (11.3) Val264Met AG 32 4 (12.5) 0.71
TT 49 7 (14.3) GG 758 84 (11.1)
F13A1 GG 443 44 (9.9) 0.23 THBD AA
Val34Leu GT 296 39 (13.2) -33G/A AG 3 1 (33.3) 0.23
TT 41 7 (17.1) GG 801 89 (11.1)
F2 AA 1 0 (0) 0.93 THBD AA 11 2 (18.2) 0.46
G20210A* AG 23 2 (8.7) Ala25Thr AG 794 87 (11)
GG 783 88 (11.2) GG
F5 AA 1 0 (0) 0.26 THBD CC 531 64 (12.1) 0.52
Arg506Gln AG 36 1 (2.8) Ala455Val CT 237 22 (9.3)
GG 769 89 (11.6) TT 24 2 (8.3)
F7 AA 16 5 (31.3) 0.01 THBS1 AA 614 66 (10.8) 0.65
Arg353Gln AG 148 19 (12.8) Asn700Ser AG 177 23 (13)
GG 629 63 (10) GG 14 1 (7.1)
FGB AA 24 0 (0) 0.10 THBS2 GG 74 10 (13.5) 0.65
-455A/G AG 247 23 (9.3) 3'UTR T/G* GT 250 25 (10)
GG 533 67 (12.6) TT 466 53 (11.4)
GJA4 CC 401 36 (9) 0.14 THBS4 CC 49 6 (12.2) 0.53
C1019T CT 313 38 (12.1) Ala387Pro CG 268 34 (12.7)
TT 78 13 (16.7) GG 486 49 (10.1)
GP1BA CC 13 1 (7.7) 0.87 THPO AA 187 25 (13.4) 0.52
-5T/C CT 168 21 (12.5) A5713G AG 374 40 (10.7)
TT 597 66 (11.1) GG 241 24 (10)
GRL AA 756 83 (11) 0.68 TLR4 AA 702 85 (12.1) 0.10
Asn363Ser AG 47 6 (12.8) Gly299Asp AG 88 4 (4.6)
GG GG 1 0 (0)
HFE AA 3 0 (0) 0.04 TNF AA 24 4 (16.7) 0.43
Cys282Tyr AG 96 18 (18.8) -308G/A AG 784 86 (11)
GG 703 70 (10) GG
HTR2A CC 286 25 (8.7) 0.13 TNFRSF1A AA 17 0 (0) 0.29
Ser102Ser CT 363 49 (13.5) Arg92Gln AG 189 19 (10.1)
TT 134 16 (11.9) GG 597 71 (11.9)
9p21 GG 114 15 (13.2) 0.33 9p21 AA 175 23 (13.1) 0.28
rs10116277 GT 365 41 (11.2) Rs10757274 AG 375 44 (11.7)
TT 243 20 (8.2) GG 226 19 (8.4)
9p21 CC 118 11 (9.3) 0.24
Rs1333040 CT 332 44 (13.3) 9p21 AA 146 17 (11.6) 0.35
TT 306 28 (9.2) Rs2383206 AG 375 46 (12.3)
9p21 AA 78 8 (10.3) 0.25 GG 249 21 (8.4)
Rs2383207** AG 366 46 (12.6)
GG 268 22 (8.2)
*HWE deviation (P < 0.05); **HWE deviation (P < 0.01)
Table 3: Kaplan-Meier analysis of mortality post-ACS for 89 genetic variants. (Continued)
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tion, APOA1 was related to a small number of deaths, and
the association of the I/I genotype of ACE1 would seem
paradoxical, given that the D/D genotype has been postu-
lated as a cardiac risk factor in most studies.
As with ACE1, the association of the F7 glutamine allele
would also have to have been considered paradoxical, a
priori, given that this allele was originally reported to be
protective against the occurrence of myocardial infarction,
and it correlates with lower F7 activity and hence lesser
coagulability. However, it was the relatively rare A/A gen-
otype of F7 that conferred the greatest risk of mortality in
our population of ACS patients, which is consistent with
the hypothesis that rare variants may have relatively large
genetic effects. Interestingly, all 5 deceased individuals
with the A/A genotype had NSTEMI, which is improbable
(P = 0.005) given that only 35% of the cases had this man-
ifestation of ACS, and 4 of 5 had either prior MI (N = 3)
or a history of revascularization (N = 1). Thus, further
study of the F7 allele is warranted, especially in NSTEMI
patients.
In contrast, it is possible to postulate a plausible cardio-
vascular risk mechanism for the hemochromatosis-associ-
ated A allele. Heterozygotes for the A allele, on average,
have relatively increased total body iron stores.[19,20] In
addition, some data indicate that iron excess may lead to
Mean P value differences (observed-random) in 50,000 simulationsFigure 2
Mean P value differences (observed-random) in 50,000 simulations. The right panel shows a skewed distribution of 
simulated random minus actual Kaplan-Meier log-rank P values (N = 89), indicating that observed P values collectively were 
lower than expected. With the removal of 16 positive associations (P < 0.1), the remaining genetic variables closely approxi-
mated a random distribution, as shown in the left panel.
Q-Q plot of Kaplan-Meier P values for 89 genetic variantsFigure 1
Q-Q plot of Kaplan-Meier P values for 89 genetic var-
iants. Observed log-rank P values for individual Kaplan-
Meier analyses are plotted against random expectations 
under the null hypothesis of no effect.
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free radical formation and thereby confer risk of myocar-
dial infarction.[21] However, a limitation of our study is
a lack of phenotypic data on serum iron stores (e.g., ferri-
tin or serum iron levels). In addition, the existing litera-
ture on HFE does not show a consistent association with
cardiac disease, and the allele was not even marginally
associated with the occurrence of ACS in our study popu-
lation.[5]
In judging the likely validity of the remaining 2 genetic
associations that remained statistically significant despite
extensive adjustment for comorbidity and treatment vari-
ables, one must consider the magnitude of the risk, the
numbers of deaths observed, as well as the relationship of
the genotypic risk pattern in the context of the functional
biology of each particular gene.[22]
The ICAM1 Lys469Glu association was related to rela-
tively increased mortality (15.9%) among individuals
with the A/A genotype (lysine homozygotes). This is
higher than the overall 11.1% mortality rate in the cohort,
and there were 43 deaths among individuals with this fre-
quent (34.0%) genotypic class. However, it is the 469Glu
allele that is postulated to have deleterious pro-inflamma-
tory effects,[23] and therefore, no biological mechanism
for this association is immediately obvious.
The strongest genetic association was detected for the rare
A allele (coding for arginine) of the IRS1 Gly972Arg poly-
morphism. Even a Bonferroni-corrected P value for this
association had borderline (P < 0.1) study-wide signifi-
cance. IRS1 is activated as an intracellular signal trans-
ducer, in adipocytes and skeletal muscle cells, when its
tyrosine residues are phosphorylated by the insulin-
bound insulin receptor, the function of which is inhibited
in vitro by the Arg972 residue, leading to decreased glu-
cose uptake.[24,25] Baroni et al (1999) reported the A
allele as a risk factor for coronary artery disease (18.9% vs.
6.8%),[25] and there have been inconsistent reports of
this polymorphism being more prevalent among diabet-
ics,[26,27] perhaps causing defective phosphatidylinosi-
tol 3-kinase interaction, peripheral insulin resistance, and
impaired insulin secretion. In addition, Harrap et al
reported a subthreshold linkage peak containing IRS1 in a
genome-wide scan of 61 sibling pairs with acute coronary
syndrome, adding to interest in the IRS1 locus as a cardiac
candidate gene.[28] However, IRS1 was not associated
with the primary occurrence of ACS in our previous case-
control analysis.[5] Moreover, due to the rarity of arginine
homozygous genotype, the association in our study pop-
ulation was largely based on the deaths of 2 individuals
among the 3 with the A/A genotype. Accordingly, further
prognostic study of this rare genotype is warranted in
larger populations of ACS patients, particularly those with
diabetes.
In 3 of the 6 nominally significant bivariate associations
described above (ACE, F7, ICAM1), the allele hypothe-
sized to be protective against ACS occurrence was associ-
ated with early death following ACS, creating an apparent
paradox. These may be false positive associations. How-
ever, such apparently paradoxical, but well-validated,
associations have been observed in prognostic studies
(e.g., the association between active smoking and lower
mortality following ACS).[29] One theoretical explana-
tion could be survivorship bias, meaning that most indi-
viduals with the genetic risk factor never survive the initial
cardiac event, and that the remaining individuals are
those with the best prognosis. Although potentially inter-
esting, this hypothesis is difficult to investigate except pro-
spectively, with ascertainment prior to the initial cardiac
event.
Conclusion
In summary, our study has provided no uneqivocal sup-
port for the hypothesis that any of 89 genetic variants in
72 genetic loci contribute to death following ACS. How-
ever, in the context of multiple genetic comparisons, and
necessarily modest numbers of deaths in a cohort of 811
individuals with ACS, it is challenging to interpret P val-
ues of borderline study-wide significance. Thus, we can
not exclude relatively modest survival effects in the 16
gene variants with P < 0.1 (Table 3). Further study of these
variants would be warranted, and meta-analysis would
augment power to detect weak effects. In addition, given
the recent success of the whole genome association
approach in the identification of 9p21 and other promis-
ing cardiovascular candidate genes, it is plausible that this
approach may have similar success in identifying genetic
risk factors for prognosis following ACS.
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